title: Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo.
abstract: OBJECTIVE
  Docetaxel (DTX) remains the only effective drug for prolonging survival and improving quality of life of metastatic castration-resistant prostate cancer (mCRPC) patients. Combination anticancer therapy encapsulating DTX and another extract of traditional Chinese medicine is one nano-sized drug delivery system promising to generate synergistic anticancer effects, to maximize the treatment effect, and to overcome multi-drug resistance. The purpose of this study is to construct lipid-polymer hybrid nanoparticles (LPNs) as nanomedicine for co-encapsulation of DTX and curcumin (CUR).
  
  
  METHODS
  DTX and CUR co-encapsulated LPNs (DTX-CUR-LPNs) were constructed. DTX-CUR-LPNs were evaluated in terms of particles size, zeta potential, drug encapsulation, and drug delivery. The cytotoxicity of the LPNs was evaluated on PC-3 human prostate carcinoma cells (PC3 cells) by MTT assays. In vivo anti-tumor effects were observed on the PC3 tumor xenografts in mice.
  
  
  RESULTS
  The particle size of DTX-CUR-LPNs was 169.6 nm with a positive zeta potential of 35.7 mV. DTX-CUR-LPNs showed highest cytotoxicity and synergistic effect of two drugs in tumor cells in vitro. In mice-bearing PC-3 tumor xenografts, the DTX-CUR-LPNs inhibited tumor growth to a greater extent than other contrast groups, without inducing any obvious side effects.
  
  
  CONCLUSIONS
  According to these results, the novel nanomedicine offers great promise for the dual drugs delivery to the prostate cancer cells, showing the potential of synergistic combination therapy for prostate cancer.
authors.affiliation: a Department of Renal Transplantation , The Second Hospital of Shandong University , Ji'nan , Shandong , PR China and.
authors.forename: Jieke
authors.initials: J
authors.lastname: Yan
authors.affiliation: b Clinical Department , Jinan Vocation College of Nursing , Ji'nan , Shandong , PR China.
authors.forename: Yuzhen
authors.initials: Y
authors.lastname: Wang
authors.affiliation: a Department of Renal Transplantation , The Second Hospital of Shandong University , Ji'nan , Shandong , PR China and.
authors.forename: Xufeng
authors.initials: X
authors.lastname: Zhang
authors.affiliation: a Department of Renal Transplantation , The Second Hospital of Shandong University , Ji'nan , Shandong , PR China and.
authors.forename: Shuangde
authors.initials: S
authors.lastname: Liu
authors.affiliation: a Department of Renal Transplantation , The Second Hospital of Shandong University , Ji'nan , Shandong , PR China and.
authors.forename: Chuan
authors.initials: C
authors.lastname: Tian
authors.affiliation: a Department of Renal Transplantation , The Second Hospital of Shandong University , Ji'nan , Shandong , PR China and.
authors.forename: Hongwei
authors.initials: H
authors.lastname: Wang
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D003474:Curcumin / Q000008:administration & dosage* / Q000494:pharmacology; D000077143:Docetaxel; D004337:Drug Carriers; D016503:Drug Delivery Systems; D064593:Heterografts / Q000737:chemistry / Q000187:drug effects*; D006801:Humans; D008055:Lipids / Q000737:chemistry*; D008297:Male; D051379:Mice; D050997:Nanomedicine / Q000379:methods*; D010316:Particle Size; D011108:Polymers / Q000737:chemistry*; D011471:Prostatic Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D043823:Taxoids / Q000008:administration & dosage* / Q000494:pharmacology
chemical_list: D004337:Drug Carriers; D008055:Lipids; D011108:Polymers; D043823:Taxoids; D000077143:Docetaxel; D003474:Curcumin
keywords: Combination anticancer therapy; dual drugs delivery; lipid–polymer hybrid nanoparticles; multi-drug resistance; synergistic effect